Cargando…
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
BACKGROUND: Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis (EAE), highlighted an inflammation-dependent synaptopathy at the basis of the neurodegenerative damage causing irreversible disability in these disorders. This synaptopathy is characteriz...
Autores principales: | Gentile, Antonietta, Musella, Alessandra, Bullitta, Silvia, Fresegna, Diego, De Vito, Francesca, Fantozzi, Roberta, Piras, Eleonora, Gargano, Francesca, Borsellino, Giovanna, Battistini, Luca, Schubart, Anna, Mandolesi, Georgia, Centonze, Diego |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002118/ https://www.ncbi.nlm.nih.gov/pubmed/27566665 http://dx.doi.org/10.1186/s12974-016-0686-4 |
Ejemplares similares
-
Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights
por: Bigaud, Marc, et al.
Publicado: (2021) -
Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018) -
Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2015) -
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
por: O’Sullivan, Catherine, et al.
Publicado: (2016) -
Tumor Necrosis Factor and Interleukin-1β Modulate Synaptic Plasticity during Neuroinflammation
por: Rizzo, Francesca Romana, et al.
Publicado: (2018)